Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment with galiximab plus rituximab in relapsed follicular non-Hodgkin's lymphoma
2006-003987-74Phase 3Terminated
- Sponsor
- Biogen
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of galiximab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL), sponsored by Biogen. Primary endpoints: Progression-Free Survival, Safety of retreatment and 1 more. Started Apr 2007; status: terminated.
02
Drugs
galiximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2006-003987-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003987-74.